Meredith K. Chuk

1.3k citations

29 papers · 858 indexed · h-index 14

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Pulmonary and Respiratory Medicine top 10%
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations

Papers in

Toxicology 2
Oncology 10
- Cancer Immunotherapy and Biomarkers 4

Co-authors: Richard Pazdur Elizabeth Fox Marc R. Theoret Frank M. Balis Brigitte C. Widemann Patricia Keegan Kun He Eva Dombi
Journals: Clinical Cancer Research (5 papers)The Oncologist (4 papers)Pediatric Blood & Cancer (3 papers)Journal of Clinical Oncology (3 papers)American Society of Clinical Oncology Educational Book (2 papers)
Partner nations: United States Japan Singapore

In The Last Decade

Meredith K. Chuk

29 papers receiving 843 citations

Peers

Countries citing papers authored by Meredith K. Chuk

Since Specialization

Citations

This map shows the geographic impact of Meredith K. Chuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meredith K. Chuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meredith K. Chuk more than expected).

Fields of papers citing papers by Meredith K. Chuk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meredith K. Chuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meredith K. Chuk. The network helps show where Meredith K. Chuk may publish in the future.

Co-authors

The 25 scholars most cited alongside Meredith K. Chuk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Meredith K. Chuk Line = papers co-authored together Meredith K. Chuk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib The Oncologist ·May Tun Saung, Lorraine Pelosof, Sandra J. Casak, Martha Donoghue, Steven J. Lemery, Mengdie Yuan, Lisa Rodríguez, Katarzyna Gajdel, Meredith K. Chuk, A. Lawalree, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola A. Fashoyin‐Aje	2021	77
2	Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials Clinical Pharmacology & Therapeutics ·Rupert W. Leong, Qi Liu, Jun Sanghyun, Jiang Liu, Yunzhao R. Ren, Peter P. Lee, Meredith K. Chuk, Gregory H. Reaman, Yaning Wang	2021	2
3	Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer Therapeutic Innovation & Regulatory Science ·P. Bonomi, Frederick N. Marty, Angeles Yaire Sumba Ortiz, Meredith K. Chuk, Alexander I. Spira, Anne C. Deitz, Gideon M. Blumenthal, Andrea Ferris, Yutao Gong, Jinghua He, B. SARSENBEKULY, Wendy Selig	2020	2
4	Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials JNCI Journal of the National Cancer Institute ·Paul G. Kluetz, Bellinda L. King‐Kallimanis, Daniel L. Suzman, Elaine Chang, A. C. Maurina, Chana Weinstock, Vishal Bhatnagar, Julia A. Beaver, Meredith K. Chuk	2020	7
5	Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs The Oncologist ·Taichi TANIGUCHI, Abhilasha Nair, Patricia Keegan, Julia A. Beaver, Paul G. Kluetz, Richard Pazdur, Meredith K. Chuk, Gideon M. Blumenthal	2019	11
6	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha L. Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B. Goldberg, Meredith K. Chuk, Paulette Mpaka-Nsenga, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M. Blumenthal, Patricia Keegan, Richard Pazdur, Marc R. Theoret	2018	112
7	A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group Pediatric Blood & Cancer ·Meredith K. Chuk, Brigitte C. Widemann, Charles G. Minard, Xiaowei Liu, AeRang Kim, M. Brooke Bernhardt, Rachel A. Kudgus, Joel M. Reid, Stephan D. Voss, Susan M. Blaney, Elizabeth Fox, Brenda J. Weigel	2018	47
8	FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen Clinical Cancer Research ·Christy Osgood, Meredith K. Chuk, Marc R. Theoret, Lan Huang, Kun He, Подойницына Анастасия Юрьевна, Patricia Keegan, Richard Pazdur	2017	42
9	Challenges in Opening and Enrolling Patients in Clinical Trials American Society of Clinical Oncology Educational Book ·Julie Vose, Meredith K. Chuk, Francis J. Giles	2017	4
10	Evaluating the potential for digital submission of expedited premarket safety reports to the FDA Nature Reviews Drug Discovery ·Sean Khozin, Meredith K. Chuk, Tamy Kim, Мохигул Эргашовна Ахматова, 全国証券取引所協議会, Geoffrey Kim, Richard Pazdur	2016	3
11	The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative Clinical Cancer Research ·Jonathan P. Jarow, Sandra J. Casak, Meredith K. Chuk, Lori A. Ehrlich, Sean Khozin	2016	17
12	Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy International Journal of Pediatric Endocrinology ·Maya Lodish, Alexandra Gkourogianni, Ethan Bornstein, Ninet Sinaii, Elizabeth Fox, Meredith K. Chuk, Leigh Marcus, Srivandana Akshintala, Frank M. Balis, Brigitte C. Widemann, Constantine A. Stratakis	2015	8
13	Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma Clinical Cancer Research ·Elizabeth Fox, Brigitte C. Widemann, Meredith K. Chuk, Leigh Marcus, Alberta Aikin, Patricia Whitcomb, Maria J. Merino, Maya Lodish, Eva Dombi, Seth M. Steinberg, Samuel A. Wells, Frank M. Balis	2013	110
14	A phase I trial and pharmacokinetic study of a 24‐hour infusion of trabectedin (Yondelis®, ET‐743) in children and adolescents with relapsed or refractory solid tumors Pediatric Blood & Cancer ·Meredith K. Chuk, Alberta Aikin, Jing Su, Brigitte C. Widemann, Peter Zannikos, Eliel Bayever, Frank M. Balis, Elizabeth Fox	2012	22
15	¹¹¹In-Octreotide Scintigraphy for Identification of Metastatic Medullary Thyroid Carcinoma in Children and Adolescents The Journal of Clinical Endocrinology & Metabolism ·Maya Lodish, Wiltrud Kruschinski Scheihing, Clara C. Chen, Ninet Sinaii, Patricia Whitcomb, Alberta Aikin, Eva Dombi, Leigh Marcus, Brigitte C. Widemann, Elizabeth Fox, Meredith K. Chuk, Frank M. Balis, Samuel A. Wells, Constantine A. Stratakis	2011	10
16	Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model Cancer Chemotherapy and Pharmacology ·Meredith K. Chuk, Diane E. Cole, Cynthia Lester McCully, Natalia A. Loktionova, Anthony E. Pegg, Robert Parker, Gary T. Pauly, Brigitte C. Widemann, Frank M. Balis, Elizabeth Fox	2010	1
17	A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors Journal of Clinical Oncology ·Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, Meredith K. Chuk, Eva Dombi, Wendy Goodspeed, Anne Goodwin, 邹德新, Nalini Jayaprakash, Marcelo Marotti, Kathryn H. Brown, 윤삼현, Peter C. Adamson, Brigitte C. Widemann, Frank M. Balis	2010	94
18	Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin Blood ·Meredith K. Chuk, Emily McIntyre, Donald Small, Patrick A. Brown	2009	13
19	Trabectedin The Oncologist ·Meredith K. Chuk, Frank M. Balis, Elizabeth Fox	2009	15
20	Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients Pediatric Blood & Cancer ·Su Young Kim, Xinyu Zhao, Leonardo Campos, Kristen Snyder, Meredith K. Chuk, David M. Loeb	2007	36

About Meredith K. Chuk

Meredith K. Chuk is a scholar working on Toxicology, Oncology, Genetics, Hematology and Statistics and Probability, having authored 29 papers that have together received 858 indexed citations. Recurring topics across this work include Biomedical Ethics and Regulation (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Sarcoma Diagnosis and Treatment (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Thyroid Cancer Diagnosis and Treatment (4 papers), Neuroendocrine Tumor Research Advances (3 papers), Glioma Diagnosis and Treatment (3 papers) and Renal cell carcinoma treatment (3 papers). The work is most often cited by research in Oncology (429 citations), Pulmonary and Respiratory Medicine (260 citations), Cancer Research (116 citations), Immunology (133 citations) and Endocrinology, Diabetes and Metabolism (97 citations). Meredith K. Chuk has collaborated with scholars based in United States, Japan and Singapore. Frequent co-authors include Richard Pazdur, Elizabeth Fox, Marc R. Theoret, Frank M. Balis, Brigitte C. Widemann, Patricia Keegan, Kun He, Eva Dombi, Maitreyee Hazarika and Sirisha L. Mushti. Their work appears in journals such as Clinical Cancer Research, The Oncologist, Pediatric Blood & Cancer, Journal of Clinical Oncology and American Society of Clinical Oncology Educational Book.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact